KORU Medical Systems Partners with SCHOTT Pharma to Develop Next-Gen Infusion System

KORU Medical Systems Expands Its Offerings with New Collaboration for Next-Generation Infusion System

KORU Medical Systems, Inc. announces a significant partnership with a global pharmaceutical company to develop an innovative subcutaneous immunoglobulin (SCIg) therapy infusion system. The collaboration involves the integration of KORU Medical's advanced infusion technology with SCHOTT Pharma's TOPPAC® prefillable polymer syringes. This new system aims to enhance the administration of established drug therapies, making it easier for patients to self-administer treatments at home. Linda Tharby, President and CEO of KORU Medical, highlights that this initiative marks a pivotal advancement in improving the infusion experience for SCIg patients, ensuring compatibility with both vials and prefilled syringes.

The new infusion system is part of a larger strategy by KORU Medical to enhance patient-centric care in the realm of subcutaneous therapies. The existing FREEDOM Syringe Infusion System, which has been operational since 1994, allows for both self-administration by patients and professional administration in healthcare facilities. The introduction of the next-generation system is expected to simplify home therapy administration, catering to the growing demand for convenient and efficient medical solutions. This development not only underscores KORU Medical's commitment to improving patient outcomes but also positions the company to play a crucial role in advancing the standards of care in subcutaneous infusion therapies.

KORU Medical's collaboration with SCHOTT Pharma represents a strategic move to leverage combined expertise in medical technology and pharmaceutical delivery systems. By focusing on creating a versatile platform that accommodates different forms of drug administration, the partnership aims to streamline processes for healthcare providers and patients alike. As KORU Medical continues to innovate in the medical technology space, the company remains dedicated to enhancing the quality of life for patients who rely on subcutaneous infusion therapies.

In addition to this new collaboration, KORU Medical also continues to support biopharmaceutical companies with customizable products tailored for clinical trials and drug development. This expansive focus allows KORU Medical to maintain its position at the forefront of medical technology innovation, ensuring that both patients and healthcare providers benefit from cutting-edge solutions that meet their evolving needs. For further details on their offerings, stakeholders can visit KORU Medical's website at www.korumedical.com.